Enzymotec (Enzymotec) Cash-to-Debt : No Debt ⁽¹⁾ (As of Sep. 2017)

View and export this data going back to 2013. Start your Free Trial

What is Enzymotec Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Enzymotec's cash to debt ratio for the quarter that ended in Sep. 2017 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Enzymotec could pay off its debt using the cash in hand for the quarter that ended in Sep. 2017.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Enzymotec's Cash-to-Debt or its related term are showing as below:

ENZY's Cash-to-Debt is not ranked ^*
in the Biotechnology industry.
Industry Median: 6.5
* Ranked among companies with meaningful Cash-to-Debt only.

Enzymotec Cash-to-Debt Historical Data

The historical data trend for Enzymotec's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Enzymotec Cash-to-Debt Chart

Enzymotec Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Cash-to-Debt

Get a 7-Day Free Trial

0.46

17.72

No Debt

Enzymotec Quarterly Data
	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17
Cash-to-Debt	Get a 7-Day Free Trial															No Debt	No Debt	No Debt	No Debt	No Debt

Competitive Comparison of Enzymotec's Cash-to-Debt

For the Biotechnology subindustry, Enzymotec's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Enzymotec's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enzymotec's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Enzymotec's Cash-to-Debt falls into.

Enzymotec Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Enzymotec's Cash to Debt Ratio for the fiscal year that ended in Dec. 2016 is calculated as:

Enzymotec had no debt ⁽¹⁾.

Enzymotec's Cash to Debt Ratio for the quarter that ended in Sep. 2017 is calculated as:

Enzymotec had no debt ⁽¹⁾.

Enzymotec (NAS:ENZY) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Enzymotec Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Enzymotec's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Enzymotec (Enzymotec) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enzymotec Ltd (NAS:ENZY) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.enzymotec.com

Enzymotec Ltd is nutritional and food ingredients company. It develops and manufactures nutritional ingredients and medical foods based on proprietary technologies. Its product portfolio includes Infat, K-Real, Enzy PS solutions, Vayacog, Vayarin and Vayaroll. The company has Nutrition and Vaya Pharma reportable segments. It derives majority of its revenues from Nutrition segment. The firm mainly operates in America, Europe, Australia, Asia, and Israel.